<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "2: Statements ", fill: "#f4c2c2"},
{source: "2: Statements ", target: "2: incorporated by reference", fill: "#f4c2c2"},
{source: "2: incorporated by reference", target: "2: Annual Report ", fill: "#f4c2c2"},
{source: "2: Annual Report ", target: "2: based on historical", fill: "#f4c2c2"},
{source: "2: based on historical", target: "2: forwardlooking", fill: "#f4c2c2"},
{source: "2: forwardlooking", target: "2: statements within", fill: "#f4c2c2"},
{source: "2: statements within", target: "2: Securities Act ", fill: "#f4c2c2"},
{source: "2: Securities Act ", target: "2: Exchange Act", fill: "#f4c2c2"},
{source: "2: Statements ", target: "10: depending heavily on", fill: "#ff4f00"},
{source: "10: depending heavily on", target: "10: most advanced product", fill: "#ff4f00"},
{source: "10: most advanced product", target: "10: rosacea which", fill: "#ff4f00"},
{source: "10: rosacea which", target: "10: still under", fill: "#ff4f00"},
{source: "10: still under", target: "10: regulatory review", fill: "#ff4f00"},
{source: "10: depending heavily on", target: "11: commercialize", fill: "#00bfff"},
{source: "11: commercialize", target: "11: significant", fill: "#00bfff"},
{source: "11: significant", target: "11: materially", fill: "#00bfff"},
{source: "11: commercialize", target: "12: significant", fill: "#a50b5e"},
{source: "12: significant", target: "12: recent efforts", fill: "#a50b5e"},
{source: "12: recent efforts", target: "12: development", fill: "#a50b5e"},
{source: "12: development", target: "12: most advanced product candidate", fill: "#a50b5e"},
{source: "12: most advanced product candidate", target: "12: Oracea ", fill: "#a50b5e"},
{source: "12: significant", target: "14: will depend on several factors", fill: "#f400a1"},
{source: "14: will depend on several factors", target: "14: marketing approvals from", fill: "#f400a1"},
{source: "14: marketing approvals from", target: "14: regulatory", fill: "#f400a1"},
{source: "14: regulatory", target: "14: authorities", fill: "#f400a1"},
{source: "14: authorities", target: "14: acceptance", fill: "#f400a1"},
{source: "14: acceptance", target: "14: product by patients", fill: "#f400a1"},
{source: "14: product by patients", target: "14: medical community", fill: "#f400a1"},
{source: "14: medical community", target: "14: third party payors", fill: "#f400a1"},
{source: "14: will depend on several factors", target: "15: successfully commercialize", fill: "#b87333"},
{source: "15: successfully commercialize", target: "15: revenue from", fill: "#b87333"},
{source: "15: revenue from", target: "15: product candidate", fill: "#b87333"},
{source: "15: product candidate", target: "15: product development programs", fill: "#b87333"},
{source: "15: successfully commercialize", target: "18: connection with", fill: "#faebd7"},
{source: "18: connection with", target: "18: regulatory approval process", fill: "#faebd7"},
{source: "18: regulatory approval process", target: "18: approved new drug", fill: "#faebd7"},
{source: "18: approved new drug", target: "18: exclusivity", fill: "#faebd7"},
{source: "18: exclusivity", target: "18: will prevent generic versions", fill: "#faebd7"},
{source: "18: will prevent generic versions", target: "18: products from entering", fill: "#faebd7"},
{source: "18: connection with", target: "19: market exclusivity", fill: "#21421e"},
{source: "19: market exclusivity", target: "19: new chemical entities", fill: "#21421e"},
{source: "19: new chemical entities", target: "19: significant", fill: "#21421e"},
{source: "19: significant", target: "19: already approved drug products such as", fill: "#21421e"},
{source: "19: market exclusivity", target: "21: United States District Court for the District ", fill: "#ff8c69"},
{source: "21: United States District Court for the District ", target: "21: application", fill: "#ff8c69"},
{source: "21: application", target: "21: Periostat ", fill: "#ff8c69"},
{source: "21: Periostat ", target: "21: market exclusivity", fill: "#ff8c69"},
{source: "21: market exclusivity", target: "21: previously been approved as", fill: "#ff8c69"},
{source: "21: United States District Court for the District ", target: "55: cannot assure", fill: "#3b444b"},
{source: "55: cannot assure", target: "55: dermatology market", fill: "#3b444b"},
{source: "55: cannot assure", target: "63: product candidate", fill: "#fe2712"},
{source: "63: product candidate", target: "63: development", fill: "#fe2712"},
{source: "63: development", target: "63: things efficacy", fill: "#fe2712"},
{source: "63: things efficacy", target: "63: safety concerns", fill: "#fe2712"},
{source: "63: safety concerns", target: "63: inability", fill: "#fe2712"},
{source: "63: inability", target: "63: necessary regulatory approvals", fill: "#fe2712"},
{source: "63: necessary regulatory approvals", target: "63: difficulty", fill: "#fe2712"},
{source: "63: difficulty", target: "63: excessive cost", fill: "#fe2712"},
{source: "63: excessive cost", target: "63: manufacture andor", fill: "#fe2712"},
{source: "63: manufacture andor", target: "63: infringement", fill: "#fe2712"},
{source: "63: infringement", target: "63: intellectual property rights", fill: "#fe2712"},
{source: "63: product candidate", target: "69: regulatory approvals", fill: "#18453b"},
{source: "69: regulatory approvals", target: "69: commercialize", fill: "#18453b"},
{source: "69: commercialize", target: "69: product candidates", fill: "#18453b"},
{source: "69: product candidates", target: "69: revenue will", fill: "#18453b"},
{source: "69: revenue will", target: "69: materially impaired", fill: "#18453b"},
{source: "69: regulatory approvals", target: "71: Periostat ", fill: "#b57281"},
{source: "71: Periostat ", target: "71: regulatory approval", fill: "#b57281"},
{source: "71: regulatory approval", target: "71: product candidates", fill: "#b57281"},
{source: "71: product candidates", target: "71: jurisdiction", fill: "#b57281"},
{source: "71: Periostat ", target: "START_HERE", fill: "#b57281"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Application Software</td>
    </tr>
    <tr>
      <td>Pharmaceuticals Biotechnology and Life Sciences</td>
    </tr>
    <tr>
      <td>Biotechnology</td>
    </tr>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Automobile Manufacturers</td>
    </tr>
    <tr>
      <td>Motorcycle Manufacturers</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Crime</td>
    </tr>
    <tr>
      <td>Leadership</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Political reform</td>
    </tr>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Rights</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Request</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Psychological state</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
    <tr>
      <td>Sanction</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Travel to meet</td>
    </tr>
    <tr>
      <td>Comment</td>
    </tr>
    <tr>
      <td>Complain</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Rally support</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_statement">Financial statement</a></td>
      <td>Financial statements (or financial reports) are formal records of the financial activities and position of a business, person, or other entity.\nRelevant financial information is presented in a structured manner and in a form which is easy to understand.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_agency">Regulatory agency</a></td>
      <td>A regulatory agency (regulatory body, regulator) or independent agency (independent regulatory agency) is a government authority that is responsible for exercising autonomous dominion over some area of human activity in a licensing and regulating capacity.\nThese are customarily set up to strengthen safety and standards, and/or to protect consumers in markets where there is a lack of effective competition.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Significant_other">Significant other</a></td>
      <td>The term significant other (SO) has different uses in psychology and in colloquial language. Colloquially "significant other" is used as a gender-neutral term for a person's partner in an intimate relationship without disclosing or presuming anything about marital status, relationship status, gender identity, or sexual orientation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bit_numbering">Bit numbering</a></td>
      <td>In computing, bit numbering is the convention used to identify the bit positions in a binary number.\n\n\n== Bit significance and indexing ==\n\nIn computing, the least significant bit (LSB) is the bit position in a binary integer representing the binary 1s place of the integer.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Significant_form">Significant form</a></td>
      <td>Significant form refers to an aesthetic theory developed by English art critic Clive Bell which specified a set of criteria for what qualified as a work of art.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Statistical_significance">Statistical significance</a></td>
      <td>In statistical hypothesis testing, a result has statistical significance when it is very unlikely to have occurred given the null hypothesis. More precisely, a study's defined significance level, denoted by \n  \n    \n      \n        α\n      \n    \n    {\displaystyle \alpha }\n  , is the probability of the study rejecting the null hypothesis, given that the null hypothesis is true; and the p-value of a result, \n  \n    \n      \n        p\n      \n    \n    {\displaystyle p}\n  , is the probability of obtaining a result at least as extreme, given that the null hypothesis is true.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/The_Simpsons">The Simpsons</a></td>
      <td>The Simpsons is an American animated sitcom created by Matt Groening for the Fox Broadcasting Company. The series is a satirical depiction of American life, epitomized by the Simpson family, which consists of Homer, Marge, Bart, Lisa, and Maggie.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Doxycycline">Doxycycline</a></td>
      <td>Doxycycline is a broad-spectrum tetracycline-class antibiotic used in the treatment of infections caused by bacteria and certain parasites. It is used to treat bacterial pneumonia, acne, chlamydia infections, Lyme disease, cholera, typhus, and syphilis.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulation">Regulation</a></td>
      <td>Regulation is the management of complex systems according to a set of rules and trends. In systems theory, these types of rules exist in various fields of biology and society, but the term has slightly different meanings according to context.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_affairs">Regulatory affairs</a></td>
      <td>Regulatory affairs (RA), also called government affairs, is a profession within regulated industries, such as pharmaceuticals, medical devices, cosmetics, agrochemicals (plant protection products and fertilizers), energy, banking, telecom etc.  Regulatory affairs also has a very specific meaning within the healthcare industries (pharmaceuticals, medical devices, biologics and functional foods).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_state">Regulatory state</a></td>
      <td>The term regulatory state refers to the expansion in the use of rulemaking, monitoring and enforcement techniques and institutions by the state and to a parallel change in the way its positive or negative functions in society are being carried out. The expansion of the state nowadays is generally via regulation and less via taxing and spending.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_law">Regulatory law</a></td>
      <td>Regulatory law refers to secondary legislation, including regulations, promulgated by an executive branch agency under a delegation from a legislature. It contrasts with statutory law promulgated by the legislative branch, and common law or case law promulgated by the judicial branch.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_sign">Regulatory sign</a></td>
      <td>A regulatory sign is used to indicate or reinforce traffic laws, regulations or requirements which apply either at all times or at specified times or places upon a street or highway, the disregard of which may constitute a violation, or a sign in general that regulates public behavior in places open to the public.  The FHWA defines regulatory sign as "a sign that gives notice to road users of traffic laws or regulations".</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_capitalism">Regulatory capitalism</a></td>
      <td>Regulatory capitalism suggests that the operation maintenance and development of the international political economy increasingly depends on administrative rules outside the legislatures and the courts. In other words, it tells us that capitalism is a regulatory institution – one that is being constituted, shaped, constrained and expanded as a historically woven patchwork of regulatory institutions, strategies, and functions.Although this patchwork varies widely across regions, nations, regimes, sectors, issues, and arenas, the general trend despite and beyond the process of liberalization is that of growth rather than decline of the role regulation in shaping policy and politics.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_capture">Regulatory capture</a></td>
      <td>In politics, regulatory capture (also agency capture and client politics) is a form of corruption of authority that occurs when a political entity, policymaker, or regulator is co-opted to serve the commercial, ideological, or political interests of a minor constituency, such as a particular geographic area, industry, profession, or ideological group.When regulatory capture occurs, a special interest is prioritized over the general interests of the public, leading to a net loss for society. The theory of client politics is related to that of rent-seeking and political failure; client politics "occurs when most or all of the benefits of a program go to some single, reasonably small interest (e.g., industry, profession, or locality) but most or all of the costs will be borne by a large number of people (for example, all taxpayers)".</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_T_cell">Regulatory T cell</a></td>
      <td>The regulatory T cells (Tregs  or Treg cells), formerly known as suppressor T cells, are a subpopulation of T cells that modulate the immune system, maintain tolerance to self-antigens, and prevent autoimmune disease. Treg cells are immunosuppressive and generally suppress or downregulate induction and proliferation of effector T cells.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_technology">Regulatory technology</a></td>
      <td>Regulatory technology, Abrv: regtech, is a new technology that uses information technology to enhance regulatory and compliance processes. Regtech expands across all industries, including: financial services, banking, technology, retail, gaming and healthcare.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Halozyme">Halozyme</a></td>
      <td>Halozyme Therapeutics is an American biotechnology company that develops novel oncology therapies designed to target the tumor microenvironment and licenses a novel drug delivery technology through corporate partnerships.\nThe company was founded in 1998 and went public in 2004.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/MannKind_Corporation">MannKind Corporation</a></td>
      <td>MannKind Corporation is a biopharmaceutical company focusing on the discovery, development, and commercialization of therapeutic products for diseases such as diabetes and pulmonary arterial hypertension. Based in Danbury, Connecticut, the company was founded in February 1991.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Medicago_Inc.">Medicago Inc.</a></td>
      <td>Medicago Inc. is a privately-owned Canadian biotechnology company focused on the discovery, development, and commercialization of virus-like particles using plants as "bioreactors" to produce proteins as candidate vaccines and medications.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Food_and_Drug_Administration">Food and Drug Administration</a></td>
      <td>The United States Food and Drug Administration (FDA or USFDA) is a federal agency of the Department of Health and Human Services. The FDA is responsible for protecting and promoting public health through the control and supervision of food safety, tobacco products, dietary supplements, prescription and over-the-counter pharmaceutical drugs (medications), vaccines, biopharmaceuticals, blood transfusions, medical devices, electromagnetic radiation emitting devices (ERED), cosmetics, animal foods &amp; feed and veterinary products.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sun_Pharma">Sun Pharma</a></td>
      <td>Sun Pharmaceutical Industries Limited (d/b/a Sun Pharma) is an Indian multinational pharmaceutical company headquartered in Mumbai, Maharashtra, that manufactures and sells pharmaceutical formulations and active pharmaceutical ingredients (APIs)  in more than 100 countries across the globe. It is largest pharma company in India and the fourth largest specialty generic pharmaceutical company in the world, with a total revenue of over US$4.5 billion as of June 2021.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Metalloprotease_inhibitor">Metalloprotease inhibitor</a></td>
      <td>Metalloprotease inhibitors are cellular inhibitors of the  Matrix metalloproteinases (MMPs). MMPs belong to a family of zinc-dependent neutral endopeptidases.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Host_modulatory_therapy">Host modulatory therapy</a></td>
      <td>Host modulatory therapy is an emerging treatment concept in the management of periodontitis that aims to reduce tissue destruction and stabilise or even regenerate the periodontium by modifying the host response. Historically treatment of periodontitis has been focused on reducing the bacterial challenge.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_drugs:_Pb–Pe">List of drugs: Pb–Pe</a></td>
      <td>This multi-page article lists pharmaceutical drugs alphabetically by name. Many drugs have more than one name and, therefore, the same drug may be listed more than once.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Stiefel_Laboratories">Stiefel Laboratories</a></td>
      <td>Stiefel Laboratories is an American dermatological pharmaceutical company, with its global headquarters in Research Triangle Park, North Carolina. It makes products such as Duac and Oilatum.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Psoriasis">Psoriasis</a></td>
      <td>Psoriasis is a long-lasting, noncontagious autoimmune disease characterized by raised areas of abnormal skin. These areas are red, or purple on some people with darker skin, dry, itchy, and scaly.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Medixsysteme">Medixsysteme</a></td>
      <td>Medixsysteme company is one of the world's manufacturers of medical equipment based in Liechtenstein. The company offers products, services and research in Medical aesthetic.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Aquaphor">Aquaphor</a></td>
      <td>Aquaphor is a brand of over-the-counter (OTC) skin care ointments manufactured by Beiersdorf Inc., an affiliate of Beiersdorf AG. Aquaphor is offered in four product ranges:  There are two skin protectant ointments. Aquaphor Original Ointment, used as a compounding agent  and Aquaphor Advanced Therapy Healing Ointment, sold in mass retail outlets.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Isotretinoin">Isotretinoin</a></td>
      <td>Isotretinoin, also known as 13-cis-retinoic acid and sold under the brand name Roaccutane among others, is a medication primarily used to treat severe acne. It is also used to prevent certain skin cancers (squamous-cell carcinoma), and in the treatment of other cancers.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Dermatitis">Dermatitis</a></td>
      <td>Dermatitis is inflammation of the skin, typically characterized by itchiness, redness and a rash. In cases of short duration, there may be small blisters, while in long-term cases the skin may become thickened.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacturing">Manufacturing</a></td>
      <td>Manufacturing is the creation or production of goods with the help of equipment, labor, machines, tools, and chemical or biological processing or formulation. It is the essence of secondary sector of the economy.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Starlink">Starlink</a></td>
      <td>Starlings are small to medium-sized passerine birds in the family Sturnidae. The name "Sturnidae" comes from the Latin word for starling, sturnus.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Aerie_Pharmaceuticals">Aerie Pharmaceuticals</a></td>
      <td>Aerie Pharmaceuticals Inc. (Nasdaq: AERI) is a publicly traded, clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Medicines_and_Healthcare_products_Regulatory_Agency">Medicines and Healthcare products Regulatory Agency</a></td>
      <td>The Medicines and Healthcare products Regulatory Agency (MHRA) is an executive agency of the Department of Health and Social Care in the United Kingdom which is responsible for ensuring that medicines and medical devices work and are acceptably safe.\nThe MHRA was formed in 2003 with the merger of the Medicines Control Agency (MCA) and the Medical Devices Agency (MDA).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Praziquantel">Praziquantel</a></td>
      <td>Praziquantel (PZQ), sold under the brandname Biltricide among others, is a medication used to treat a number of types of parasitic worm infections in mammals, birds, amphibians, reptiles, and fish. In humans specifically, it is used to treat schistosomiasis, clonorchiasis, opisthorchiasis, tapeworm infections, cysticercosis, hydatid disease, and other fluke infections.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Denosumab">Denosumab</a></td>
      <td>Denosumab (trade names Prolia and Xgeva) is a human monoclonal antibody for the treatment of osteoporosis, treatment-induced bone loss, metastases to bone, and giant cell tumor of bone.Denosumab is contraindicated in people with low blood calcium levels. The most common side effects are joint and muscle pain in the arms or legs.Denosumab is a inhibitor of RANKL (receptor activator of nuclear factor kappa-Β ligand), which works by preventing the development of osteoclasts, which are cells that break down bone.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>COLLAGENEX PHARMACEUTICALS INC      Item 1A                <font color="blue">Risk Factors</font></td>
    </tr>
    <tr>
      <td><font color="blue">Statements </font>contained or <font color="blue">incorporated by reference</font> in this <font color="blue">Annual Report </font>on     Form 10-K  that  are not <font color="blue"><font color="blue">based on</font> historical</font> fact are “forward-looking     statements” within the meaning of the Private Securities Litigation Reform     Act of 1995, Section 27A of the <font color="blue">Securities Act </font>of 1933, as amended, and     Section 21E of the <font color="blue">Exchange Act</font></td>
    </tr>
    <tr>
      <td>These forward-looking statements regarding     <font color="blue">future events</font> and our future results are <font color="blue"><font color="blue">based on</font> current <font color="blue">expectations</font></font>,     estimates, forecasts, and <font color="blue">projections</font> and the beliefs and <font color="blue">assumptions</font> of our     <font color="blue">management</font> including, <font color="blue">without limitation</font>, our <font color="blue">expectations</font> regarding results     of <font color="blue">operations</font>, selling, general and <font color="blue">administrative</font> expenses, research and     <font color="blue"><font color="blue">development</font> expenses</font>, the <font color="blue">sufficiency</font> of our cash for <font color="blue">future <font color="blue">operations</font></font>, and     the success of our preclinical, clinical and <font color="blue"><font color="blue">development</font> programs</font> and our     <font color="blue"><font color="blue">dermatology</font> franchise</font></td>
    </tr>
    <tr>
      <td>Forward-looking <font color="blue">statements may</font> be identified by the     use  of  forward-looking  <font color="blue">terminology</font>  such as “may,” “could,” “will,”     “expect,” “estimate,” “anticipate,” “continue,” or similar terms, <font color="blue">variations</font>     of such terms or the negative of those terms</td>
    </tr>
    <tr>
      <td>We <font color="blue"><font color="blue">cannot assure</font> investors</font> that our <font color="blue">assumptions</font> and <font color="blue">expectations</font> will prove     to have been correct</td>
    </tr>
    <tr>
      <td><font color="blue">Important </font><font color="blue">factors could</font> cause our actual results to     differ  <font color="blue">materially</font>  from those indicated or implied by forward-looking     statements</td>
    </tr>
    <tr>
      <td>Such factors that could cause or contribute to <font color="blue">such differences</font>     include  those  factors  discussed below</td>
    </tr>
    <tr>
      <td>We undertake <font color="blue">no intention</font> or     <font color="blue">obligation</font> to update or revise any forward-looking statements, whether as a     result  of  new information, <font color="blue">future events</font> or otherwise</td>
    </tr>
    <tr>
      <td>If any of the     <font color="blue">following risks actually</font> occur, our business, <font color="blue">financial condition</font> or results     of <font color="blue"><font color="blue"><font color="blue">operations</font> would</font> likely suffer</font></td>
    </tr>
    <tr>
      <td>We  are  <font color="blue">depending <font color="blue">heavily on</font></font> the success of our <font color="blue">most advanced product</font>     candidate,  Oracea, for the treatment of rosacea, which is <font color="blue">still under</font>     <font color="blue"><font color="blue">regulatory</font> review</font></td>
    </tr>
    <tr>
      <td>If we are unable to obtain approval for and <font color="blue">commercialize</font>     Oracea, or experience <font color="blue">significant</font> delays in doing so, our business will be     <font color="blue">materially</font> harmed</td>
    </tr>
    <tr>
      <td>We have invested a <font color="blue">significant</font> portion of our <font color="blue">recent efforts</font> and financial     resources in the <font color="blue">development</font> of our <font color="blue">most advanced product</font> candidate, Oracea,     for the treatment of rosacea</td>
    </tr>
    <tr>
      <td>Our ability to       16     ______________________________________________________________________       generate substantial <font color="blue"><font color="blue">product revenues</font> from</font> Oracea, if ever, will depend     <font color="blue">heavily on</font> the successful <font color="blue">development</font> and <font color="blue">commercialization</font> of Oracea</td>
    </tr>
    <tr>
      <td>The     success of Oracea <font color="blue">will depend on several factors</font>, including the following:       ·       receipt of <font color="blue"><font color="blue">marketing approval</font>s from</font> the FDA and similar foreign     <font color="blue">regulatory</font> <font color="blue">authorities</font>; and       ·       <font color="blue">acceptance</font> of the <font color="blue">product by patients</font>, the <font color="blue">medical community</font> and     <font color="blue"><font color="blue">third party</font> payors</font></td>
    </tr>
    <tr>
      <td>If we are unable to obtain FDA approval for and <font color="blue">successfully</font> <font color="blue">commercialize</font>     Oracea, we may never realize <font color="blue">revenue from</font> this <font color="blue">product candidate</font> and we may     have to curtail our other product <font color="blue"><font color="blue">development</font> programs</font></td>
    </tr>
    <tr>
      <td>As a result, our     business would be <font color="blue">materially</font> harmed</td>
    </tr>
    <tr>
      <td>We cannot rely on <font color="blue">regulatory</font> protections to prevent the approval of generic     <font color="blue">equivalents</font> of our products</td>
    </tr>
    <tr>
      <td>In <font color="blue">connection with</font> the <font color="blue">regulatory</font> approval process, some <font color="blue">approved new drug</font>     products can obtain <font color="blue">exclusivity</font> that <font color="blue">will prevent <font color="blue"><font color="blue">generic version</font>s</font></font> of the     <font color="blue"><font color="blue">products from</font> entering</font> the marketplace for a period of time</td>
    </tr>
    <tr>
      <td>In the United     States, market <font color="blue">exclusivity</font> is available for <font color="blue">new chemical entities</font> and for     <font color="blue">significant</font> changes in already approved drug products, such as a new use</td>
    </tr>
    <tr>
      <td>Market <font color="blue">exclusivity</font> is, however, not available to drugs that contain an     active  ingredient that has <font color="blue">already been approved as</font> an antibiotic</td>
    </tr>
    <tr>
      <td>On     January 19, 2005, the <font color="blue"><font color="blue"><font color="blue">United States</font> </font>District Court for the District </font>of     Columbia upheld the FDA’s <font color="blue">application</font> of this principle to <font color="blue">Periostat </font>and     determined that <font color="blue">Periostat </font>was not entitled to market <font color="blue">exclusivity</font> because its     active  ingredient,  doxycycline,  had  <font color="blue">previously been approved as</font> an     antibiotic</td>
    </tr>
    <tr>
      <td>Because  Oracea  also  <font color="blue">contains doxycycline as</font> its active     ingredient, it will also not be entitled to market <font color="blue">exclusivity</font></td>
    </tr>
    <tr>
      <td><font color="blue">In the <font color="blue">European Community</font> </font><font color="blue">regulatory</font> market <font color="blue">exclusivity</font> is a function of how     long  the  competent  <font color="blue">authorities</font> may determine that <font color="blue">data submitted</font> in     <font color="blue">marketing approval</font> <font color="blue">application</font>s may not be <font color="blue">referenced by others</font></td>
    </tr>
    <tr>
      <td>The period     of so-called data <font color="blue">exclusivity</font> to which a <font color="blue">new <font color="blue">product may</font></font> be entitled can     <font color="blue">vary from eleven years</font> to none at all</td>
    </tr>
    <tr>
      <td>This <font color="blue">depends on how</font> a product is     classified and can turn on the <font color="blue">application</font> of <font color="blue">regulatory</font> standards of which     there has <font color="blue">been no authoritative interpretation</font> to date</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot predict</font>     what period of data <font color="blue">exclusivity</font>, if any, may be <font color="blue">enjoyed by</font> Oracea in the     <font color="blue">European Community</font></td>
    </tr>
    <tr>
      <td>With limited or no market <font color="blue">exclusivity</font> it can be more <font color="blue">difficult</font> for us to     <font color="blue">prevent <font color="blue"><font color="blue">competitor</font>s</font> from seeking approval</font> for copies of our <font color="blue">proprietary</font>     products, and in such a case the value of <font color="blue">such products would</font> be <font color="blue">materially</font>     <font color="blue">adversely affected</font></td>
    </tr>
    <tr>
      <td>Without market <font color="blue">exclusivity</font>, <font color="blue"><font color="blue">generic version</font>s</font> of our     <font color="blue"><font color="blue">products could</font> quickly gain market entry</font> if they meet <font color="blue">regulatory</font> approval     criteria</td>
    </tr>
    <tr>
      <td>Thus, even if we <font color="blue">gain approval</font> of Oracea, because it will not be     entitled to patent or non-patent market <font color="blue">exclusivity</font>, <font color="blue">third parties</font> may enter     the market which would <font color="blue">materially</font> harm our business</td>
    </tr>
    <tr>
      <td>If we are not able to obtain and <font color="blue">enforce <font color="blue">patent protection</font></font> for Oracea or our     other <font color="blue">discoveries</font>, our ability to <font color="blue">commercialize</font> our <font color="blue">product candidate</font>s     <font color="blue">successfully</font> will be harmed and we may not be able to operate our business     profitably</td>
    </tr>
    <tr>
      <td>Our <font color="blue">success depends</font>, in part, on our ability to protect <font color="blue">proprietary</font> methods     and <font color="blue">technologies</font> that we develop under the patent and other <font color="blue">intellectual</font>     <font color="blue">property laws</font> of the <font color="blue"><font color="blue">United States</font> </font>and other countries, so that we can     prevent  <font color="blue">others from using</font> our <font color="blue">inventions</font> and <font color="blue">proprietary</font> information</td>
    </tr>
    <tr>
      <td>However, we may not hold <font color="blue">proprietary</font> rights to some patents related to our     current or <font color="blue">future products</font> and <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>Because patent <font color="blue">application</font>s in     the <font color="blue"><font color="blue">United States</font> </font>and many foreign <font color="blue"><font color="blue">jurisdiction</font>s</font> are typically not published     until 18 months after filing, or in some cases not at all, and because     <font color="blue">publications</font> of <font color="blue">discoveries</font> in <font color="blue">scientific literature lag behind actual</font>     <font color="blue">discoveries</font>,  we  cannot be certain that we were the first to make the     <font color="blue">inventions</font> claimed in <font color="blue">issued patents</font> or pending patent <font color="blue">application</font>s, or that     we were the first to file for protection of the <font color="blue">inventions</font> set forth in our     patent <font color="blue">application</font>s</td>
    </tr>
    <tr>
      <td>There are, for instance, patent applicants that claim     to have <font color="blue">invented elements</font> of the SansRosa <font color="blue"><font color="blue">technology</font> prior</font> to SansRosa’s     patent <font color="blue">application</font> filing date</td>
    </tr>
    <tr>
      <td>As a result, we       17     ______________________________________________________________________       may be required to obtain licenses under third-party patents to market our     proposed products</td>
    </tr>
    <tr>
      <td>If licenses are not available to us on acceptable terms,     or at all, we will not be able to market the <font color="blue">affected products</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">strategy depends on</font> our ability to identify our <font color="blue">discoveries</font> rapidly and     to <font color="blue">seek <font color="blue">patent protection</font></font> for them</td>
    </tr>
    <tr>
      <td>This process is expensive and time     consuming, and we may not be able to file and prosecute all <font color="blue">necessary</font> or     desirable patent <font color="blue">application</font>s at a <font color="blue">reasonable cost</font> or in a <font color="blue">timely manner</font></td>
    </tr>
    <tr>
      <td>Despite our efforts to protect our <font color="blue">proprietary</font> rights, unauthorized parties     may be able to obtain and use information that we regard as <font color="blue">proprietary</font></td>
    </tr>
    <tr>
      <td>The     issuance of a patent does not guarantee that it is valid or enforceable, so     even if we obtain patents, they may not be valid or <font color="blue">enforceable against</font>     <font color="blue">third parties</font></td>
    </tr>
    <tr>
      <td>In addition, the issuance of a patent does not guarantee that     we have the right to practice the <font color="blue">patented invention</font></td>
    </tr>
    <tr>
      <td>Third <font color="blue">parties may</font> have     <font color="blue">blocking patents</font> that could be used to <font color="blue">prevent us from marketing</font> our own     <font color="blue">patented product</font> and practicing our own <font color="blue">patented <font color="blue">technology</font></font></td>
    </tr>
    <tr>
      <td>Our pending patent <font color="blue">application</font>s may not result in <font color="blue">issued patents</font></td>
    </tr>
    <tr>
      <td>The patent     position of <font color="blue">pharmaceutical</font> or <font color="blue"><font color="blue">bio<font color="blue">technology</font></font> companies</font>, including ours, is     <font color="blue"><font color="blue">generally</font> uncertain</font> and <font color="blue">involves complex legal</font> and factual <font color="blue">considerations</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">standards which</font> the USPTO and its foreign <font color="blue">counterparts</font> use to grant     patents are not always applied <font color="blue">predictably</font> or uniformly and can change</td>
    </tr>
    <tr>
      <td>There is also no uniform, worldwide policy regarding the subject matter and     scope of claims granted or allowable in <font color="blue">pharmaceutical</font> or <font color="blue">bio<font color="blue">technology</font></font>     patents</td>
    </tr>
    <tr>
      <td>The laws of some foreign countries do not protect <font color="blue">proprietary</font>     information to the <font color="blue">same extent as</font> the laws of the <font color="blue">United States</font>, and many     companies have <font color="blue">encountered</font> <font color="blue">significant</font> problems and costs in protecting     their <font color="blue">proprietary</font> information in these foreign countries</td>
    </tr>
    <tr>
      <td>Accordingly, we do     not know the degree of <font color="blue">future protection</font> for our <font color="blue">proprietary</font> rights or the     breadth of claims allowed in any <font color="blue">patents issued</font> to us or to others</td>
    </tr>
    <tr>
      <td>The     allowance of broader claims may increase the incidence and cost of patent     interference <font color="blue">proceedings</font> and/or opposition <font color="blue">proceedings</font>, and the risk of     <font color="blue"><font color="blue">infringement</font> <font color="blue">litigation</font></font></td>
    </tr>
    <tr>
      <td>On the other hand, the allowance of narrower claims     may limit the value of our <font color="blue">proprietary</font> rights</td>
    </tr>
    <tr>
      <td>If issued, our patent for Oracea may not contain claims <font color="blue">sufficiently broad</font>     to protect us against <font color="blue">third parties</font> with similar products, or <font color="blue">provide us</font>     with any <font color="blue"><font color="blue">competitive</font> advantage</font></td>
    </tr>
    <tr>
      <td>Moreover, <font color="blue">once issued</font>, any of our patents     may be challenged, narrowed, invalidated or <font color="blue">circumvented</font></td>
    </tr>
    <tr>
      <td>In addition, the     <font color="blue">patent rights</font> in our products that <font color="blue">derive from</font> claims <font color="blue">under method</font> of use     patents may be hard to assert or enforce if <font color="blue">medical professionals prescribe</font>     similar (including generic), though non-approved, doxycycline products for     <font color="blue"><font color="blue">indication</font>s</font>  <font color="blue">covered by</font> our patents</td>
    </tr>
    <tr>
      <td>If our patents are invalidated or     otherwise limited, other <font color="blue">companies will</font> be <font color="blue">better able</font> to develop products     and <font color="blue">technologies</font> that compete with ours, which could adversely affect our     <font color="blue">competitive</font> business position, business prospects and <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that our pursuit of business in the <font color="blue"><font color="blue">dermatology</font> market</font>     will be successful</td>
    </tr>
    <tr>
      <td>We continue to implement our plans to <font color="blue">expand into</font> the <font color="blue"><font color="blue">dermatology</font> market</font></td>
    </tr>
    <tr>
      <td>We     <font color="blue">recently submitted</font> an NDA with the <font color="blue">FDA for Oracea </font>to treat rosacea, and we     continue to seek <font color="blue">additional</font> product licensing <font color="blue">opportunities</font> to enhance our     near-term offerings to the <font color="blue"><font color="blue">dermatology</font> market</font></td>
    </tr>
    <tr>
      <td>We have <font color="blue">also been allowed by</font>     the USPTO a patent for the use of sub-anti-microbial <font color="blue">tetracyclines</font> for the     treatment of acne and <font color="blue">acne rosacea</font>, including Oracea</td>
    </tr>
    <tr>
      <td>While we have experience in the sales and marketing of <font color="blue">dental products</font>, we     have limited experience in the <font color="blue"><font color="blue">dermatology</font> market</font></td>
    </tr>
    <tr>
      <td>This market is very     <font color="blue">competitive</font> and some of our <font color="blue"><font color="blue">competitor</font>s</font> have <font color="blue"><font color="blue">substantially</font> greater resources</font>     than we have</td>
    </tr>
    <tr>
      <td>Our future success will depend on, among other things, our     ability  to:  (i) achieve  market <font color="blue">acceptance</font> for any current or future     dermatological offerings; (ii) hire and retain <font color="blue">personnel with</font> experience in     the <font color="blue"><font color="blue">dermatology</font> market</font>; (iii) execute our business plan <font color="blue">with respect</font> to this     market segment; and (iv) adapt to technical or <font color="blue">regulatory</font> changes once     operational</td>
    </tr>
    <tr>
      <td>At  the  same  time, new product <font color="blue">development</font> is a lengthy, complex and     uncertain process that will require <font color="blue">significant</font> attention and resources from     <font color="blue">management</font></td>
    </tr>
    <tr>
      <td>A <font color="blue">product candidate</font> can fail at any stage of the <font color="blue">development</font>     process  due  to, among other things, efficacy or <font color="blue">safety concerns</font>, the     <font color="blue">inability</font>  to obtain <font color="blue">necessary</font> <font color="blue">regulatory</font> approvals, the <font color="blue">difficult</font>y or     <font color="blue">excessive cost</font> to <font color="blue">manufacture</font> and/or the <font color="blue">infringement</font> of       18     ______________________________________________________________________       patents or <font color="blue">intellectual</font> property rights of others</td>
    </tr>
    <tr>
      <td>Furthermore, the sales of     <font color="blue">new products</font> may prove to be <font color="blue">disappointing</font> and fail to reach anticipated     levels</td>
    </tr>
    <tr>
      <td>We therefore <font color="blue">cannot assure</font> you that we will be successful in our     pursuit of business in the <font color="blue"><font color="blue">dermatology</font> market</font>, or that we can sustain any     business in which we achieve <font color="blue">initial success</font></td>
    </tr>
    <tr>
      <td>The success of our <font color="blue">current <font color="blue">technology</font> platforms</font>, and that of any other     <font color="blue">future <font color="blue">technology</font> platforms</font> we may purchase or in-license, will depend on     the  quality and integrity of the <font color="blue">technologies</font> licensed or sold to us</td>
    </tr>
    <tr>
      <td>Despite our due diligence and the <font color="blue">safeguards</font> we have in place, we cannot     guarantee the <font color="blue"><font color="blue">effective</font>ness</font> or integrity of such <font color="blue">technologies</font>, nor can we be     certain that others do not have <font color="blue">intervening rights</font> in such <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>If     any of our in-licensed <font color="blue">technologies</font> proved in<font color="blue">effective</font>, or if a <font color="blue">third party</font>     <font color="blue">successfully</font> asserted any right to such <font color="blue">technologies</font>, our ability to develop     <font color="blue">new products</font> and implement our <font color="blue">strategies would</font> be <font color="blue">materially</font> adversely     affected</td>
    </tr>
    <tr>
      <td>If we are not able to obtain required <font color="blue">regulatory</font> approvals, we will not be     able to <font color="blue">commercialize</font> our <font color="blue">product candidate</font>s, and our ability to generate     <font color="blue">revenue will</font> be <font color="blue">materially</font> impaired</td>
    </tr>
    <tr>
      <td>Failure to obtain <font color="blue">regulatory</font> approval for a <font color="blue">product candidate</font> will prevent     <font color="blue">us from <font color="blue">commercializing</font></font> the <font color="blue">product candidate</font></td>
    </tr>
    <tr>
      <td>Other than Periostat, we have     not received <font color="blue">regulatory</font> approval to market any of our <font color="blue">product candidate</font>s in     any <font color="blue">jurisdiction</font></td>
    </tr>
    <tr>
      <td>We have only limited experience in filing and prosecuting     the  <font color="blue">application</font>s <font color="blue">necessary</font> to gain <font color="blue">regulatory</font> approvals</td>
    </tr>
    <tr>
      <td><font color="blue">Securing FDA     </font>approval requires the submission of extensive preclinical and <font color="blue">clinical data</font>,     information  about  product  <font color="blue"><font color="blue">manufacturing</font> processes</font> and inspection of     <font color="blue">facilities</font>  and supporting information to the FDA for each <font color="blue">therapeutic</font>     <font color="blue">indication</font> to establish the <font color="blue">product candidate</font>’s safety and efficacy</td>
    </tr>
    <tr>
      <td>Our     <font color="blue">future products</font> may not be <font color="blue">effective</font>, may be <font color="blue">only moderately <font color="blue">effective</font></font> or     may prove to have undesirable or unintended side effects, toxicities or     other <font color="blue">characteristics</font> that may preclude our obtaining <font color="blue">regulatory</font> approval or     prevent or <font color="blue">limit commercial use</font></td>
    </tr>
    <tr>
      <td>The process of obtaining <font color="blue">regulatory</font> approvals is expensive, often takes many     years, if approval is obtained at all, and can <font color="blue">vary <font color="blue">substantially</font> based</font>     upon, among other things, the type, <font color="blue">complexity</font> and novelty of the product     <font color="blue">candidates</font> involved</td>
    </tr>
    <tr>
      <td>Changes in the <font color="blue">regulatory</font> approval policy during the     <font color="blue">development</font> period, changes in or the <font color="blue">enactment</font> of <font color="blue">additional</font> statutes or     <font color="blue">regulations</font>, or changes in <font color="blue"><font color="blue">regulatory</font> review</font> for <font color="blue">each submitted product</font>     <font color="blue">application</font>,  may  cause  delays  in  the  approval or rejection of an     <font color="blue">application</font></td>
    </tr>
    <tr>
      <td>The FDA, and comparable <font color="blue">authorities</font> in other countries, have substantial     <font color="blue">discretion</font> in the approval process and may refuse to accept any <font color="blue">application</font>     or  may  decide that our data is insufficient for approval and require     <font color="blue">additional</font> preclinical, clinical or other studies</td>
    </tr>
    <tr>
      <td>In addition, varying     <font color="blue">interpretations</font> of the data obtained <font color="blue">from preclinical</font> and <font color="blue">clinical testing</font>     <font color="blue">could influence how</font> a <font color="blue">product candidate</font> is classified and delay, limit or     prevent <font color="blue">regulatory</font> approval of a <font color="blue">product candidate</font></td>
    </tr>
    <tr>
      <td>Any <font color="blue">regulatory</font> approval     we  ultimately  obtain  may  be  limited or subject to <font color="blue">restrictions</font> or     post-approval commitments that render the product not <font color="blue">commercially viable</font></td>
    </tr>
    <tr>
      <td>Even if <font color="blue">regulatory</font> approval of a product is granted, the <font color="blue">approval may</font> be     subject to <font color="blue">limitations on</font> the <font color="blue">indicated uses</font> for which the <font color="blue">product may</font> be     marketed or to the <font color="blue">conditions</font> of approval, or <font color="blue">contain <font color="blue">requirements</font></font> for     costly post-marketing testing and surveillance to monitor the safety or     efficacy of the product</td>
    </tr>
    <tr>
      <td>If we lose our <font color="blue">sole supplier</font> of doxycycline or our <font color="blue"><font color="blue">manufacture</font>r</font> of Oracea,     our sales of Oracea, if any, will be interrupted, halted or <font color="blue">less profitable</font></td>
    </tr>
    <tr>
      <td>We do not have the resources, <font color="blue">facilities</font> or <font color="blue">capabilities</font> to <font color="blue">manufacture</font> any     of  our  products  or <font color="blue">product candidate</font>s</td>
    </tr>
    <tr>
      <td>We have no current plans to     establish a <font color="blue"><font color="blue">manufacturing</font> facility</font></td>
    </tr>
    <tr>
      <td>We expect that we will be <font color="blue">dependent</font>, to     a  <font color="blue">significant</font>  extent, on contract <font color="blue"><font color="blue">manufacture</font>r</font>s for <font color="blue">commercial scale</font>     <font color="blue">manufacturing</font> of our products or <font color="blue">product candidate</font>s in <font color="blue">accordance with</font>     <font color="blue">regulatory</font> standards</td>
    </tr>
    <tr>
      <td>19     ______________________________________________________________________       We rely on a <font color="blue">single supplier</font>, Hovione International Limited, or Hovione, for     doxycycline, the active ingredient in Oracea</td>
    </tr>
    <tr>
      <td>There are <font color="blue">relatively few</font>     <font color="blue">alternative suppliers</font> of doxycycline and Hovione produces the majority of     the <font color="blue">doxycycline used</font> in the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">current supply <font color="blue">agreement</font> with</font>     Hovione <font color="blue">expires on</font> May 14, 2006 and thereafter automatically renews for     successive two-year periods unless, 90 days prior to the expiration of any     such  periods,  either  party  gives the other <font color="blue">party written</font> notice of     <font color="blue">termination</font></td>
    </tr>
    <tr>
      <td>In addition, in the event of a default, uncured for 90 days,     the  non-defaulting party can terminate the <font color="blue">supply <font color="blue"><font color="blue">agreement</font> <font color="blue">effective</font></font></font>     <font color="blue">immediately at</font> the end of such ninety-day period</td>
    </tr>
    <tr>
      <td>We rely on Hovione as our     <font color="blue">sole supplier</font> of doxycycline and have no back-up supplier at this time</td>
    </tr>
    <tr>
      <td>Although  Hovione maintains two <font color="blue">manufacturing</font> locations, if we achieve     FDA approval for Oracea and are unable to procure a commercial quantity of     doxycycline from Hovione on an <font color="blue">ongoing basis at</font> a <font color="blue">competitive</font> price, if     <font color="blue">Hovione  </font>fails to <font color="blue">comply with cGMP</font>, or if we <font color="blue">cannot find</font> a <font color="blue">replacement</font>     supplier in a <font color="blue">timely manner</font> or with favorable <font color="blue">pricing terms</font>, our costs may     increase <font color="blue">significant</font>ly and we may experience delays in the supply of Oracea</td>
    </tr>
    <tr>
      <td>We <font color="blue">entered into</font> an <font color="blue"><font color="blue">agreement</font> <font color="blue">effective</font></font> <font color="blue">December </font>31, 2005 with PTS, pursuant     to which PTS has agreed to <font color="blue">manufacture</font> Oracea for us</td>
    </tr>
    <tr>
      <td>Pursuant to the terms     of  the <font color="blue">agreement</font>, we agree to (i) furnish to PTS on a <font color="blue">monthly basis</font> a     <font color="blue">rolling forecast</font> of product quantities for the subsequent twelve-month     period, the <font color="blue">first three months</font> of <font color="blue">which shall become binding</font>, and (ii) pay     PTS a fee for the product, subject to an <font color="blue">annual adjustment</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">agreement</font>     has an <font color="blue">initial term</font> of <font color="blue">four years unless terminated earlier pursuant</font> to its     terms</td>
    </tr>
    <tr>
      <td>We intend to contract with <font color="blue">additional</font> <font color="blue"><font color="blue">manufacture</font>r</font>s for the commercial     <font color="blue">manufacture</font> of an Oracea capsule</td>
    </tr>
    <tr>
      <td>We believe, however, that it could take     up to one year to validate <font color="blue">successfully</font> a secondary <font color="blue"><font color="blue">manufacture</font>r</font></td>
    </tr>
    <tr>
      <td>We cannot     be certain that we will be able to enter into <font color="blue">additional</font> <font color="blue">agreement</font>s on     acceptable terms, if at all</td>
    </tr>
    <tr>
      <td>In the event that Oracea is <font color="blue">approved by</font> the FDA     and we are unable to obtain sufficient quantities of doxycycline or <font color="blue">Oracea     </font><font color="blue">on commercially reasonable terms</font>, or in a <font color="blue">timely manner</font>, our business,     <font color="blue">financial condition</font> and results of <font color="blue"><font color="blue">operations</font> would</font> be <font color="blue">materially</font> adversely     affected</td>
    </tr>
    <tr>
      <td>If the federal <font color="blue">regulatory</font> status of Alcortin or Novacort changes, we may be     unable to continue to <font color="blue">market one</font> or both of these products</td>
    </tr>
    <tr>
      <td>We  market  <font color="blue">two products</font>, Alcortin and Novacort, under a <font color="blue">Promotion </font>and     <font color="blue">Cooperation Agreement </font>with Primus</td>
    </tr>
    <tr>
      <td>The majority of sample <font color="blue">product costs</font> and     all  <font color="blue">sales force compensation</font> related to our promotion of Alcortin and     Novacort are <font color="blue">funded by us</font></td>
    </tr>
    <tr>
      <td>Primus is responsible for the <font color="blue">manufacture</font> of     Alcortin and Novacort and it has not sought FDA approval for these products     because it believes that no approval is required</td>
    </tr>
    <tr>
      <td><font color="blue">If the FDA </font>were     to assert that these products required approval, it could at any time seek     to take <font color="blue">administrative</font> or <font color="blue">judicial actions which could prevent us from</font>     marketing these products</td>
    </tr>
    <tr>
      <td>Our <font color="blue">inability</font> to market these <font color="blue">products could</font>     result in a temporary or <font color="blue">permanent loss</font> of revenue, which may be partially     <font color="blue">offset by</font> a reduction in our <font color="blue">promotional expenses</font> related to these products</td>
    </tr>
    <tr>
      <td>Our <font color="blue">products could</font> be subject to <font color="blue">restrictions</font> or <font color="blue">withdrawal from</font> the market     and we may be subject to penalties if we fail to comply with <font color="blue">regulatory</font>     <font color="blue">requirements</font></td>
    </tr>
    <tr>
      <td>Both before and after approval or clearance, we, our vendors     and  suppliers, and our products and <font color="blue">product candidate</font>s are subject to     extensive <font color="blue">regulatory</font> <font color="blue">requirements</font></td>
    </tr>
    <tr>
      <td>Failure to comply with these <font color="blue">requirements</font>     could subject us to <font color="blue">administrative</font> and judicial sanctions</td>
    </tr>
    <tr>
      <td>Both  before  and after approval or clearance of our products, we, our     products,  and  our  <font color="blue"><font color="blue">manufacture</font>r</font>s are subject to extensive <font color="blue">regulatory</font>     <font color="blue">requirements</font> covering, among other things, <font color="blue">manufacturing</font>, advertising and     promotion, labeling, adverse event reporting, post-approval commitments,     registration, record-keeping, export, and <font color="blue">distribution</font> of samples</td>
    </tr>
    <tr>
      <td><font color="blue">Failure     </font>to comply with <font color="blue">regulatory</font> <font color="blue">requirements</font> may result in:       ·        <font color="blue">restrictions</font> on such products, <font color="blue"><font color="blue">manufacture</font>r</font>s or <font color="blue">manufacturing</font>     processes;       ·       warning letters;       20     ______________________________________________________________________       ·       withdrawal of the <font color="blue">products from</font> the market;       ·       refusal to approve pending <font color="blue">application</font>s or <font color="blue">supplements</font> to approved     <font color="blue">application</font>s that we submit;       ·       recall;       ·       fines;       ·       suspension or withdrawal of <font color="blue">regulatory</font> approvals;       ·       refusal to permit the import or export of our products;       ·       <font color="blue">product seizure</font>; and       ·       <font color="blue">injunctions</font> or the imposition of civil or <font color="blue">criminal penalties</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot predict</font> with certainty the effect on our business of the decline     in <font color="blue">revenues generated by</font> the dental business following the <font color="blue">commercial launch</font>     of <font color="blue"><font color="blue">generic version</font>s</font> of <font color="blue">Periostat </font>and the <font color="blue">termination</font> of our <font color="blue">dental sales</font>     force</td>
    </tr>
    <tr>
      <td>We have <font color="blue">historically relied on sales</font> of <font color="blue">Periostat </font>and Mutual’s branded     version of Periostat, together with <font color="blue">revenues generated by</font> the other products     that made up our dental business, for most of our revenue</td>
    </tr>
    <tr>
      <td>During the years     ended <font color="blue">December </font>31, 2005, 2004 and 2003, <font color="blue">Periostat </font>and Mutual’s branded     version  of  <font color="blue">Periostat </font><font color="blue">supplied by us</font> (<font color="blue">with respect</font> to the years ended     <font color="blue">December </font>31, 2005 and 2004), accounted for approximately 76prca, 88prca and 82prca of     our total net revenues, respectively</td>
    </tr>
    <tr>
      <td>On May 13, 2005, the FDA approved a <font color="blue">third party</font> <font color="blue">generic version</font> of <font color="blue">Periostat </font>    and a <font color="blue">generic product</font> was <font color="blue">launched soon thereafter</font> in late May 2005</td>
    </tr>
    <tr>
      <td><font color="blue">Upon     </font>this <font color="blue">generic launch</font>, Mutual was <font color="blue">no longer obligated</font> to purchase and is not     expected to purchase their <font color="blue">branded product from us</font></td>
    </tr>
    <tr>
      <td>We do not anticipate     <font color="blue">future shipments</font> of Mutual’s <font color="blue">branded version</font> of <font color="blue">Periostat </font><font color="blue">supplied by us</font></td>
    </tr>
    <tr>
      <td>In     addition,  we  have had to disband our <font color="blue">dental sales</font> force and delay or     <font color="blue">discontinue</font>  <font color="blue">certain research</font> and <font color="blue">development</font> <font color="blue">activities</font> in the dental     business</td>
    </tr>
    <tr>
      <td>Consequently, while we continue to <font color="blue">generate cash flow from</font> our     dental business, our revenues and <font color="blue">margins from</font> <font color="blue">Periostat </font>and the other     dental  products  we sell have decreased <font color="blue">significant</font>ly and <font color="blue">will likely</font>     continue  to <font color="blue">decrease as</font> a result of the <font color="blue">third party</font> introduction of a     <font color="blue">generic version</font> of Periostat</td>
    </tr>
    <tr>
      <td>If this decrease is more <font color="blue">significant</font> than we     expect, and is <font color="blue">combined with slow growth</font> in, or a lack of revenues, if any,     from <font color="blue">new products</font>, we may experience <font color="blue">difficult</font>y in managing our cash, which     could have a material adverse effect on our ability execute our strategies     and develop our <font color="blue">dermatology</font> business</td>
    </tr>
    <tr>
      <td>We will need substantial <font color="blue">additional</font> funding and may be unable to raise     capital when needed, <font color="blue">which would force us</font> to delay, reduce or eliminate our     product <font color="blue"><font color="blue">development</font> programs</font> and <font color="blue">commercialization</font> efforts</td>
    </tr>
    <tr>
      <td>We  expect that our research and <font color="blue"><font color="blue">development</font> expenses</font> will increase in     <font color="blue">connection with</font> our <font color="blue">ongoing <font color="blue">activities</font></font> and that we will incur <font color="blue">significant</font>     <font color="blue">commercialization</font> expenses as we expand our marketing and <font color="blue">sales efforts</font></td>
    </tr>
    <tr>
      <td>We     will need substantial <font color="blue">additional</font> funding and may be unable to <font color="blue">raise capital</font>     when needed or on attractive terms, <font color="blue">which would force us</font> to delay, reduce or     eliminate  our research and <font color="blue"><font color="blue">development</font> programs</font> and <font color="blue">commercialization</font>     <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td>We  anticipate  that our current cash, cash <font color="blue">equivalents</font> and short-term     investments at <font color="blue">December </font>31, 2005, together with the <font color="blue">additional</font> dlra11dtta7 million     in <font color="blue">net proceeds from</font> the 1cmam350cmam000 <font color="blue">additional</font> shares of <font color="blue"><font color="blue">common stock</font> sold</font> in     January 2006, will be sufficient to fund our <font color="blue"><font color="blue">operations</font> through at least</font>     mid-2007</td>
    </tr>
    <tr>
      <td>However, our forecast of the period of time <font color="blue">through which</font> our     <font color="blue">financial resources will</font> be adequate to support our <font color="blue"><font color="blue">operations</font> involves</font>     risks and <font color="blue">uncertainties</font>, and actual results could vary <font color="blue">materially</font></td>
    </tr>
    <tr>
      <td>Our     future funding <font color="blue">requirements</font> will depend on many factors, including:       ·        the  cost  of <font color="blue">commercialization</font> <font color="blue">activities</font>, including product     marketing and sales;       ·       the success of our <font color="blue"><font color="blue">dermatology</font> franchise</font>;       21     ______________________________________________________________________       ·       the success of our preclinical, clinical and <font color="blue"><font color="blue">development</font> programs</font>;       ·       revenues and <font color="blue">profits from sales</font> of Periostat, Pandel and our other     <font color="blue">product candidate</font>s, as well as the products we co-promote;       ·       the terms and <font color="blue">conditions</font> of our outstanding Series D-1 Stock;       ·       our ability to continue to meet the covenant <font color="blue">requirements</font> under our     revolving credit <font color="blue">facility with</font> Silicon Valley Bank;       ·       the <font color="blue">costs involved</font> in preparing, filing, prosecuting, maintaining     and  enforcing patent claims and other patent-related costs, including     <font color="blue">potential <font color="blue">litigation</font> costs</font> and the results of <font color="blue">such <font color="blue">litigation</font></font>;       ·       the extent to which we acquire or invest in businesses, products and     <font color="blue">technologies</font>;       ·       the <font color="blue">costs involved</font> in obtaining <font color="blue">regulatory</font> approvals and <font color="blue">clearances</font>     required to market and sell our products;       ·       our ability to establish and maintain <font color="blue">additional</font> collaborations; and       ·       the <font color="blue">receptivity</font> of the <font color="blue">capital markets</font> to our <font color="blue">future <font color="blue">financings</font></font></td>
    </tr>
    <tr>
      <td>Until such time, if ever, as we can generate substantial <font color="blue">product revenues</font>,     we  expect  to finance our cash needs <font color="blue">through public</font> or <font color="blue">private equity</font>     offerings,  debt  <font color="blue">financings</font> and <font color="blue">corporate collaboration</font> and licensing     <font color="blue">arrangements</font></td>
    </tr>
    <tr>
      <td>If we raise <font color="blue">additional</font> funds by issuing equity securities,     our <font color="blue"><font color="blue">stockholders</font> may</font> experience dilution</td>
    </tr>
    <tr>
      <td>Debt financing, if available, may     involve  <font color="blue">agreement</font>s that include <font color="blue">covenants limiting</font> or restricting our     ability to take specific actions, such as incurring <font color="blue">additional</font> debt, making     capital  <font color="blue">expenditures</font>  or  declaring dividends</td>
    </tr>
    <tr>
      <td>Any <font color="blue">debt financing</font> or     <font color="blue">additional</font> equity that we raise may contain terms, such as liquidation and     other <font color="blue">preferences</font>, that are not favorable to us or our <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>If we     raise <font color="blue">additional</font> funds through collaboration and licensing <font color="blue">arrangements</font> with     <font color="blue">third parties</font>, it may be <font color="blue">necessary</font> to <font color="blue">relinquish</font> valuable rights to our     <font color="blue">technologies</font>, research programs or products or <font color="blue">grant licenses on terms</font> that     may not be favorable to us</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that our <font color="blue"><font color="blue">clinical trial</font>s will</font> be completed in a timely     manner or will meet agreed upon end-points</td>
    </tr>
    <tr>
      <td>As part of our plans to <font color="blue">expand into</font> the <font color="blue"><font color="blue">dermatology</font> market</font>, we will need to     conduct  extensive testing of our products, pursuant to protocols that     measure end <font color="blue">points agreed with</font> the FDA or other <font color="blue">regulatory</font> agencies</td>
    </tr>
    <tr>
      <td>We     cannot  guarantee that Phase I, Phase II, or Phase III testing for our     products in <font color="blue">development</font> will be completed <font color="blue">successfully</font> within any specified     period of time, if at all</td>
    </tr>
    <tr>
      <td>Many products that initially appear promising are     found, after <font color="blue">clinical evaluation</font>, not to be safe and <font color="blue">effective</font></td>
    </tr>
    <tr>
      <td>Also, we, or     the  FDA,  <font color="blue">may suspend <font color="blue">clinical trial</font>s at</font> any time <font color="blue">on various grounds</font>,     including a finding that the subjects or patients are being exposed to an     unacceptable <font color="blue">health risk</font></td>
    </tr>
    <tr>
      <td>Delays in patient <font color="blue">enrollment</font> in <font color="blue">clinical trial</font>s may result in increased     costs  and delays, which could have a harmful effect on our ability to     develop products</td>
    </tr>
    <tr>
      <td>It may take <font color="blue">several years</font> to complete the testing of a product, and failure     can occur at any stage of testing</td>
    </tr>
    <tr>
      <td>For example:       ·        interim  results  of  preclinical  or <font color="blue">clinical studies</font> do not     <font color="blue">necessarily predict</font> their final results, and results in <font color="blue">early studies might</font>     not be seen in <font color="blue">later studies</font>;       ·        potential  products  that appear <font color="blue">promising at early stages</font> of     <font color="blue">development</font> may ultimately fail for a number of reasons, including the     <font color="blue">possibility</font>  that the <font color="blue">products may</font> be in<font color="blue">effective</font>, less <font color="blue">effective</font> than     products of our <font color="blue"><font color="blue">competitor</font>s</font> or cause harmful side effects;       22     ______________________________________________________________________       ·        any  preclinical or <font color="blue">clinical test may fail</font> to produce results     satisfactory to the FDA or foreign <font color="blue">regulatory</font> <font color="blue">authorities</font>;       ·       preclinical and <font color="blue">clinical data</font> can be interpreted in <font color="blue">different</font> ways,     which could delay, limit or prevent <font color="blue">regulatory</font> approval;       ·       we may not be able to <font color="blue">manufacture</font> the <font color="blue">investigational</font> or commercial     product in sufficient quantity or quality or at acceptable cost;       ·        negative  or <font color="blue">inconclusive</font> results from a preclinical study or     <font color="blue">clinical trial</font> or adverse medical events during a <font color="blue">clinical trial</font> could cause     a preclinical study or <font color="blue">clinical trial</font> to be repeated or a program to be     terminated, even if other studies or trials relating to the program are     successful;       ·        the  FDA can place a hold on a <font color="blue">clinical trial</font> if, among other     reasons,  it finds that <font color="blue">patients enrolled</font> in the trial are or would be     exposed to an unreasonable and <font color="blue">significant</font> risk of illness or injury;       ·       we <font color="blue">may encounter delays</font> or <font color="blue">rejections <font color="blue">based on</font></font> changes in <font color="blue">regulatory</font>     <font color="blue">agency policies during</font> the period in which we develop a drug or the period     required for review of any <font color="blue">application</font> for <font color="blue">regulatory</font> agency approval; and       ·       our <font color="blue">clinical trial</font>s may not <font color="blue">demonstrate</font> the safety and efficacy     needed for our products to receive <font color="blue">regulatory</font> approval</td>
    </tr>
    <tr>
      <td>If we are required to conduct <font color="blue">additional</font> <font color="blue">clinical trial</font>s or other studies     beyond those that we currently contemplate, if we are unable to <font color="blue">successfully</font>     complete our <font color="blue">clinical trial</font>s or other studies or if the results of these     trials or studies are not positive or are <font color="blue">only modestly</font> positive, we may be     delayed  in obtaining <font color="blue">marketing approval</font>, we may not be able to obtain     <font color="blue">marketing approval</font> or we may obtain approval for <font color="blue"><font color="blue">indication</font>s</font> that are not as     <font color="blue">broad as intended</font></td>
    </tr>
    <tr>
      <td>Our product <font color="blue">development</font> costs will also increase if we     experience delays in testing or approvals</td>
    </tr>
    <tr>
      <td><font color="blue">Significant </font><font color="blue">clinical trial</font> delays     <font color="blue">could allow</font> our <font color="blue"><font color="blue">competitor</font>s</font> to <font color="blue">bring products</font> to market before we do and     impair our ability to <font color="blue">commercialize</font> our products or <font color="blue">potential products</font></td>
    </tr>
    <tr>
      <td>If     any of this occurs, our business will be <font color="blue">materially</font> harmed</td>
    </tr>
    <tr>
      <td>If we infringe or are alleged to infringe <font color="blue">intellectual</font> property rights of     <font color="blue">third parties</font>, it <font color="blue">will adversely affect</font> our business</td>
    </tr>
    <tr>
      <td>Our research, <font color="blue">development</font> and <font color="blue">commercialization</font> <font color="blue">activities</font>, as well as any     <font color="blue">product candidate</font>s or products resulting from these <font color="blue">activities</font>, may infringe     or be claimed to <font color="blue">infringe patents</font> or patent <font color="blue">application</font>s under which we do     not hold licenses or other rights</td>
    </tr>
    <tr>
      <td>Third <font color="blue">parties may</font> own or control these     patents and patent <font color="blue">application</font>s in the <font color="blue"><font color="blue">United States</font> </font>and abroad</td>
    </tr>
    <tr>
      <td>These third     <font color="blue">parties could bring</font> claims <font color="blue">against us</font> or our <font color="blue">collaborators</font> that would cause     us to incur substantial expenses and, if successful <font color="blue">against us</font>, could cause     us to pay substantial damages</td>
    </tr>
    <tr>
      <td>Further, if a patent <font color="blue">infringement</font> suit were     brought <font color="blue">against us</font> or our <font color="blue">collaborators</font>, we or they could be forced to stop     or delay research, <font color="blue">development</font>, <font color="blue">manufacturing</font> or sales of the product or     <font color="blue">product candidate</font> that is the subject of the suit</td>
    </tr>
    <tr>
      <td>As a result of patent <font color="blue">infringement</font> claims, or in order to <font color="blue">avoid potential</font>     claims, we or our <font color="blue">collaborators</font> may choose or be required to seek a license     from the <font color="blue">third party</font> and be required to <font color="blue">pay license fees</font> or royalties or     both</td>
    </tr>
    <tr>
      <td>These <font color="blue">licenses may</font> not be <font color="blue">available on</font> acceptable terms, or at all</td>
    </tr>
    <tr>
      <td>Even if we or our <font color="blue">collaborators</font> were able to obtain a license, the rights     may be nonexclusive, which could result in our <font color="blue"><font color="blue">competitor</font>s</font> gaining access to     the same <font color="blue">intellectual</font> property</td>
    </tr>
    <tr>
      <td>Ultimately, we could be <font color="blue">prevented from</font>     <font color="blue">commercializing</font> a product, or be forced to cease some aspect of our business     <font color="blue">operations</font>, if, as a result of actual or threatened patent <font color="blue">infringement</font>     claims,  we  or our <font color="blue">collaborators</font> are unable to <font color="blue">enter into licenses on</font>     acceptable terms</td>
    </tr>
    <tr>
      <td>This <font color="blue">could harm</font> our business <font color="blue">significant</font>ly</td>
    </tr>
    <tr>
      <td>23     ______________________________________________________________________       There has been substantial <font color="blue">litigation</font> and other <font color="blue">proceedings</font> regarding patent     and  other  <font color="blue">intellectual</font>  property  rights  in  the <font color="blue">pharmaceutical</font> and     <font color="blue">bio<font color="blue">technology</font></font> industries</td>
    </tr>
    <tr>
      <td>In addition to <font color="blue">infringement</font> claims <font color="blue">against us</font>, we     may  become  a party to other patent <font color="blue">litigation</font> and other <font color="blue">proceedings</font>,     including interference <font color="blue">proceedings</font> declared by the USPTO and opposition     <font color="blue">proceedings</font> in the European Patent Office, regarding <font color="blue">intellectual</font> property     rights <font color="blue">with respect</font> to our products and <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>The cost to us of any     patent <font color="blue">litigation</font> or other proceeding, even if resolved in our favor, could     be substantial</td>
    </tr>
    <tr>
      <td>Some of our <font color="blue"><font color="blue">competitor</font>s</font> may be able to sustain the costs of     <font color="blue">such <font color="blue">litigation</font></font> or <font color="blue">proceedings</font> more <font color="blue">effective</font>ly than we can because of their     <font color="blue">substantially</font> greater financial resources</td>
    </tr>
    <tr>
      <td><font color="blue">Uncertainties </font>resulting from the     <font color="blue">initiation</font> and <font color="blue">continuation</font> of patent <font color="blue">litigation</font> or other <font color="blue">proceedings</font> could     have a material adverse effect on our ability to compete in the marketplace</td>
    </tr>
    <tr>
      <td>Patent  <font color="blue">litigation</font>  and  other <font color="blue">proceedings</font> may also absorb <font color="blue">significant</font>     <font color="blue">management</font> time</td>
    </tr>
    <tr>
      <td>We depend upon <font color="blue">third party</font> researchers and providers of <font color="blue">clinical services</font> to     perform <font color="blue">as contractually</font> required if we are to be successful in <font color="blue">bringing new</font>     products to market</td>
    </tr>
    <tr>
      <td>We do not have the ability in<font color="blue">dependent</font>ly to conduct the <font color="blue">clinical trial</font>s     required  to  obtain  <font color="blue">regulatory</font> approval for our products</td>
    </tr>
    <tr>
      <td>We rely on     in<font color="blue">dependent</font> clinical investigators, contract research organizations and     other <font color="blue">third party</font> service providers for <font color="blue">successful execution</font> of our clinical     trials,  but  do  not control many aspects of their <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td>We are     responsible for ensuring that each of our <font color="blue">clinical trial</font>s is conducted in     <font color="blue">accordance with</font> the general <font color="blue">investigational</font> plan, protocols for the trial     and applicable <font color="blue">regulatory</font> <font color="blue">requirements</font></td>
    </tr>
    <tr>
      <td>Moreover, the FDA requires us to     comply with standards, commonly referred to as Good Clinical Practices, for     conducting and recording and reporting the results of <font color="blue">clinical trial</font>s to     assure that data and reported results are credible and accurate and that the     rights, integrity and <font color="blue">confidentiality</font> of trial <font color="blue">participants</font> are protected</td>
    </tr>
    <tr>
      <td>Our reliance on <font color="blue">third parties</font> that we do not control does not <font color="blue">relieve us</font> of     these <font color="blue">responsibilities</font> and <font color="blue">requirements</font></td>
    </tr>
    <tr>
      <td>Third <font color="blue">parties may</font> not, however,     complete <font color="blue">activities</font> on schedule, or may not conduct our <font color="blue">clinical trial</font>s in     <font color="blue">accordance with</font> <font color="blue">regulatory</font> <font color="blue">requirements</font> or our stated protocols</td>
    </tr>
    <tr>
      <td><font color="blue">Furthermore </font>    the data that they generate may not be accurate or may, in extreme cases, be     <font color="blue">fraudulent</font></td>
    </tr>
    <tr>
      <td>Our ability to bring our <font color="blue">future products</font> to <font color="blue">market depends on</font> the quality     and integrity of the data we present to <font color="blue">regulatory</font> <font color="blue">authorities</font> in order to     obtain <font color="blue">marketing authorizations</font></td>
    </tr>
    <tr>
      <td>We cannot guarantee the <font color="blue">authenticity</font> or     accuracy of such data, nor can we be certain that such data has not been     <font color="blue">fraudulent</font>ly generated</td>
    </tr>
    <tr>
      <td>The failure of these <font color="blue">third parties</font> to carry out     their <font color="blue">obligation</font>s would <font color="blue">materially</font> adversely affect our ability to develop     and market <font color="blue">new products</font> and implement our strategies</td>
    </tr>
    <tr>
      <td>We <font color="blue">depend upon certain key relationships</font> to generate much of the <font color="blue">technology</font>     required to maintain our <font color="blue">competitive</font> position in the marketplace</td>
    </tr>
    <tr>
      <td><font color="blue">Our IMPACS </font><font color="blue">technology</font> is <font color="blue">licensed from</font> SUNY, or <font color="blue">the SUNY License</font>, and other     academic and <font color="blue">research institutions collaborating with</font> SUNY Under the SUNY     License, we have an <font color="blue">exclusive worldwide license</font> to SUNY’s rights in certain     patents  and  patent  <font color="blue">application</font>s to make and <font color="blue">sell products employing</font>     <font color="blue">tetracyclines</font> to treat certain disease <font color="blue">conditions</font></td>
    </tr>
    <tr>
      <td><font color="blue">The SUNY License </font>imposes     <font color="blue">various payment</font> and reporting <font color="blue">obligation</font>s on us, and our failure to comply     with these <font color="blue">requirements</font> permits SUNY to terminate <font color="blue">the SUNY License</font></td>
    </tr>
    <tr>
      <td>If the     SUNY License is terminated, we would lose our right to exclude <font color="blue"><font color="blue">competitor</font>s</font>     from  <font color="blue">commercializing</font>  similar products, and we could be <font color="blue">excluded from</font>     marketing the <font color="blue">same products</font> if SUNY licensed the underlying <font color="blue">technology</font> to a     <font color="blue">competitor</font>  after  <font color="blue">terminating</font>  the  SUNY License</td>
    </tr>
    <tr>
      <td><font color="blue">The SUNY License </font>is     <font color="blue">terminable by</font> SUNY on 90 days prior notice only upon our failure to make     timely payments, reimbursements or reports, if the failure is not cured by     us within 90 days</td>
    </tr>
    <tr>
      <td>The <font color="blue">termination</font> of <font color="blue">the SUNY License</font>, or the failure to     obtain and maintain <font color="blue">patent protection</font> for our <font color="blue">technologies</font>, would have a     material adverse effect on our business, <font color="blue">financial condition</font>, liquidity and     results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>24     ______________________________________________________________________       If  our  products cause injuries, we may incur <font color="blue">significant</font> expense and     <font color="blue">liability</font></td>
    </tr>
    <tr>
      <td>Our business may be <font color="blue">adversely affected</font> by potential product <font color="blue">liability</font> claims     arising out of the testing, <font color="blue">manufacturing</font> and marketing of <font color="blue">Periostat </font>and     other products developed by or for us or for which we have licensing or     promotion and <font color="blue">cooperation rights</font></td>
    </tr>
    <tr>
      <td>We have an aggregate of dlra10 million in     product <font color="blue">liability</font> insurance covering <font color="blue">Periostat </font>and Mutual’s <font color="blue">branded version</font>     of  Periostat,  our  <font color="blue">product candidate</font>s and products for which we have     licensing or promotion and <font color="blue">cooperation rights</font></td>
    </tr>
    <tr>
      <td>Our insurer has <font color="blue">also notified us</font> that our general product <font color="blue">liability</font> policy     will not cover claims arising from our past sales of Vioxx, to the extent     such claims are made after <font color="blue">December </font>31, 2004</td>
    </tr>
    <tr>
      <td>This does not affect our     <font color="blue">rights under</font> the Co-<font color="blue">Promotion </font>Agreement with Merck, which provides for     indemnification of us by Merck against any claims arising from <font color="blue">manufacturing</font>     or <font color="blue">design defects</font> in the Vioxx product or for which we, as the seller of the     product, may be <font color="blue">strictly liable as</font> a seller of an <font color="blue">inherently dangerous</font>     product</td>
    </tr>
    <tr>
      <td>Our  <font color="blue">insurance may</font> not adequately protect us against product <font color="blue">liability</font>     claims</td>
    </tr>
    <tr>
      <td><font color="blue">Insufficient  </font>insurance  coverage  or  the  failure to obtain     indemnification from <font color="blue">third parties</font> for their <font color="blue">respective liabilities may</font>     expose us to product <font color="blue">liability</font> claims and/or recalls and could cause our     business, <font color="blue">financial condition</font> and results of <font color="blue">operations</font> to decline</td>
    </tr>
    <tr>
      <td>Changes in stock option <font color="blue">accounting</font> rules may have a <font color="blue">significant</font> adverse     affect on our operating results</td>
    </tr>
    <tr>
      <td>We have a history of <font color="blue">using broad based employee stock option programs</font> to     hire, incentive and retain our workforce in a <font color="blue">competitive</font> marketplace</td>
    </tr>
    <tr>
      <td><font color="blue"><font color="blue">Statement </font> </font>of  Financial <font color="blue">Accounting </font>Standards Nodtta 123, “<font color="blue">Accounting </font>for     Stock-Based Compensation,” allows companies the choice of <font color="blue">either using</font> a     <font color="blue"><font color="blue">fair value</font> method</font> of <font color="blue">accounting</font> for options that would result in expense     <font color="blue">recognition</font> for all <font color="blue">options granted</font>, or using an intrinsic value method, as     <font color="blue">prescribed by</font> <font color="blue">Accounting </font>Principles Board Opinion Nodtta 25, “<font color="blue">Accounting </font>for     Stock Issued to Employees,” or APB 25, with a <font color="blue">pro forma disclosure</font> of the     impact on net income (loss) allocable to common <font color="blue">stockholders</font> of using the     <font color="blue">fair value</font> option expense <font color="blue">recognition</font> method</td>
    </tr>
    <tr>
      <td>We have elected to apply APB     25 and, <font color="blue">accordingly</font>, we <font color="blue">generally</font> have not recognized any <font color="blue">expense with</font>     respect to <font color="blue">employee stock options as long as such options</font> are granted at     <font color="blue">exercise prices</font> equal to the <font color="blue">fair value</font> of our <font color="blue"><font color="blue">common stock</font> on</font> the date of     grant</td>
    </tr>
    <tr>
      <td>In <font color="blue">December </font>2004, the Financial <font color="blue">Accounting </font>Standards Board issued SFAS     Nodtta 123 (revised), “Share-Based Payment” (<font color="blue">Statement </font>123R)</td>
    </tr>
    <tr>
      <td><font color="blue">Statement </font>123R     requires  that  the  <font color="blue">compensation cost</font> relating to share-based payment     <font color="blue">transactions</font>  be recognized in <font color="blue">financial statements</font></td>
    </tr>
    <tr>
      <td>That cost will be     measured  <font color="blue">based on</font> the grant-date <font color="blue">fair value</font> of the <font color="blue">equity instruments</font>     issued, which may be determined <font color="blue">with references</font> to <font color="blue">various valuation models</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">models may involve</font> extensive and <font color="blue">complex analysis</font></td>
    </tr>
    <tr>
      <td><font color="blue">Statement </font>123R is     <font color="blue">effective</font> for <font color="blue">us beginning on</font> January 1, 2006, which is the first day of our     2006 fiscal year</td>
    </tr>
    <tr>
      <td>We are in the process of reviewing <font color="blue">Statement </font>123R to     determine which <font color="blue">fair value</font> de<font color="blue">termination</font> model is <font color="blue">most appropriate</font> for us</td>
    </tr>
    <tr>
      <td>While we continue to evaluate the effect that the adoption of <font color="blue">Statement </font>123R     will have on our <font color="blue">financial position</font> and results of <font color="blue">operations</font>, we currently     expect  that  our adoption of <font color="blue">Statement </font>123R <font color="blue">will adversely affect</font> our     operating results to some extent in <font color="blue">future periods</font></td>
    </tr>
    <tr>
      <td>Our  stock  price is <font color="blue">highly volatile</font> and, therefore, the value of your     investment may fluctuate <font color="blue">significant</font>ly</td>
    </tr>
    <tr>
      <td>The <font color="blue">market price</font> of our <font color="blue">common stock</font> has fluctuated and <font color="blue">may continue</font> to     <font color="blue">fluctuate as</font> a result of <font color="blue">variations</font> in our quarterly operating results</td>
    </tr>
    <tr>
      <td>These <font color="blue"><font color="blue">fluctuations</font> may</font> be <font color="blue">exaggerated</font> if the <font color="blue">trading volume</font> of our common     stock is low</td>
    </tr>
    <tr>
      <td>In addition, the <font color="blue">stock market</font> in general has experienced     <font color="blue">dramatic price</font> and <font color="blue">volume <font color="blue">fluctuations</font> from</font> time to time</td>
    </tr>
    <tr>
      <td>These <font color="blue">fluctuations</font>     may or may not be <font color="blue">based upon</font> any business or operating results</td>
    </tr>
    <tr>
      <td>Our common     stock  may  experience  similar or even more <font color="blue">dramatic price</font> and volume     <font color="blue">fluctuations</font> that <font color="blue">may continue</font> indefinitely</td>
    </tr>
    <tr>
      <td>25     ______________________________________________________________________       The <font color="blue">following table sets forth</font> the high and <font color="blue">low last sale prices per</font> share     for  our <font color="blue">common stock</font> for each of the quarters in the <font color="blue">period beginning</font>     January 1,  2003  through <font color="blue">December </font>31, 2005, as reported on the Nasdaq     National Market:                                 Quarter Ended                               High               Low               March 31, 2003                                   $       11dtta03                                   $       6dtta66                                   June 30, 2003                                   $       13dtta27                                   $       8dtta62                                   <font color="blue">September </font>30, 2003                                   $       15dtta84                                   $       10dtta50                                   <font color="blue">December </font>31, 2003                                   $       11dtta82                                   $       8dtta90                                   March 31, 2004                                   $       14dtta16                                   $       10dtta07                                   June 30, 2004                                   $       13dtta21                                   $       8dtta70                                   <font color="blue">September </font>30, 2004                                   $       9dtta49                                   $       6dtta09                                   <font color="blue">December </font>31, 2004                                   $       7dtta49                                   $       5dtta37                                   March 31, 2005                                   $       7dtta52                                   $       4dtta50                                   June 30, 2005                                   $       7dtta61                                   $       3dtta99                                   <font color="blue">September </font>30, 2005                                   $       9dtta95                                   $       7dtta15                                   <font color="blue">December </font>31, 2005                                   $       12dtta07                                   $       8dtta50</td>
    </tr>
  </tbody>
</table>